onc meds (NAPLEX)

0.0(0)
Studied by 0 people
call kaiCall Kai
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/48

encourage image

There's no tags or description

Looks like no tags are added yet.

Last updated 6:23 PM on 6/22/26
Name
Mastery
Learn
Test
Matching
Spaced
Call with Kai

No analytics yet

Send a link to your students to track their progress

49 Terms

1
New cards

Cell Cycle Nonspecific (3 classes)

• Alkylating agents

• Anthracyclines

• Platinum compounds

All Awesome Pharmacists

2
New cards

S-Phase (2 classes)

• Antimetabolites

• Topo I inhibitors

AT the S-phase, the DNA replicATes

3
New cards

G2 phase (2 drugs)

• Etoposide

• Bleomycin

4
New cards

M phase (2 classes)

• Taxanes

• Vinca alkaloids

5
New cards

ALKYLATING AGENTS (4)

• Cyclophosphamide

• Ifosfamide

• Busulfan

• Carmustine

6
New cards

Hemorrhagic cystitis is caused y the toxic metabolite ______

acrolein

7
New cards

What chemoprotectant is given with all ifosfamide and high cyclophosphamide doses (>1 g/m2)?

MESNA

8
New cards

PLATINUM ANALOGS (3)

• Cisplatin

• Carboplatin

• Oxaliplatin

9
New cards

Platinum based safety concerns (4)

• Hypersensitivity rxn

• Nephrotoxicity (prevent with hydration, amifostine chemoprotectant, and limit dose to <100 mg/m2 per cycle)

• Ototoxicity

• Peripheral neuropathy

10
New cards

What specific adverse effect does oxaliplatin have?

Acute neuropathy exacerated by cold

11
New cards

ANTHRACYCLINES (1)

• Doxorubicin

12
New cards

Doxorubicin safety concerns (2)

• Cardiotoxicity (LVEF)

• Red discoloration

13
New cards

Doxorubicin

A. Red discoloration of body fluids

B. Blue discoloration of body fluids

A. Red discoloration of body fluids

<p>A. Red discoloration of body fluids</p>
14
New cards

Mitoxantrone

A. Red discoloration of body fluids

B. Blue discoloration of body fluids

B. Blue discoloration of body fluids

<p>B. Blue discoloration of body fluids</p>
15
New cards

How to prevent doxorubicin induced cardiotoxicity? (4)

• Limit total lifetime cumulative dose to 450-550 mg/m2

• Consider dexrazoxane chemoprotectant when cumulative dose ≥ 300

• Monitor LVEF with ECHO before and after treatment

16
New cards

TOPO I INHIBITOR

• Irinotecan

17
New cards

How to prevent & treat diarrhea with irinotecan?

• Symptomatic care, hydration, replete lights

• PPX: acute diarrhea - atropine

• TX: acute diarrhea - atropine

- Delayed diarrhea: loperamide

18
New cards

TOPO II INHIBITOR (1)

• Etoposide

19
New cards

VINCA ALKALOID (2)

• Vincristine

• Vinblastine

- VinCristine causes more CNS tox

- VinBlastine causes more Bone marrow suppression

20
New cards

Vincristine safety concerns (3)

• Peripheral neuropathy - limit single doses to 2 mg

• Autonomic neuropathy (constipation)

• Paralysis & death if given intrathecally - prepare in small IV piggyback bags with label

21
New cards

What medication can cause paralysis & death if given intrathecally?

Vincristine

22
New cards

TAXANES (2)

• Paclitaxel

• Docetaxel

23
New cards

Taxanes safety concerns (2)

• Peripheral neuropathy

• Hypersensitivity reactions - premedication

24
New cards

What taxane can cause severe fluid retention?

Docetaxel

25
New cards

PYRIMIDINE ANALOG ANTIMETABOLITES (2)

• Fluorouracil

• Capecitabine

26
New cards

Pyrimidine analog safety concerns

• Hand-foot syndrome (PPE)

• Diarrhea

• Mucositis

• Increased risk of DPD deficiency - antidote is uridine triacetate

• Significantly increase INR

27
New cards

What is the antidote for pyrimidine analog antimetabolite DPD deficiency?

Uridine Triacetate

28
New cards

Hand foot syndrome management (5)

• Use EMOLLIENTS (aquaphor, urea cream, etc)

• Limit friction & pressure

• Avoid heat exposure

• Cold compresses to provide temporary relief

• Topical steroids & pain meds if needed

29
New cards

FOLATE ANTIMETABOLITES (1)

• Methotrexate

30
New cards

Methotrexate safety concerns

• Nephrotoxicity with high doses ≥500

• GI toxicity (diarrhea, mucositis)

31
New cards

How to PPX & TX methotrexate induced nephrotoxicity?

• PPX: leucovorin rescue

- hydration with IV sodium bicarb to alkalinze the urine

- avoid NSAIDs, salicylates

• TX: antidote - glucarpidase which rapidly lowers MTX levels

32
New cards

What can glucarpidase be used for?

Treatment of methotrexate induced nephrotoxicity

33
New cards

Leucovorin rescue is required for doses ≥ ____ to reduce toxicities

500

34
New cards

VITAMIN B9 (folate) name

LEUCOVORIN

35
New cards

Oral mucositis management (5)

• Good oral hygiene (soft toothbrush)

• Ice chips

• Freq rinsing with bland rinses (sodium bicarb)

• TX with viscous lidocaine 2%, magic mouthwash

• Thrush TX: nystatin oral suspension, clotrimazole troches

36
New cards

Arsenic trioxide main safety concern (1)

QT prolongation

37
New cards

Bleomycin safety concerns (2)

• Pulmonary toxicity - lifetime cumulative dose to 400 units

• Hypersensitivity reactions

38
New cards

Bortezomib safety concern (1)

• Herpes reactivation

39
New cards

With what medication do you need 2 negative pregnancy before treatment?

Thalidomide

40
New cards

Anthracylines extravasation

A. cold compress + dexrazoxane

B. warm compress + hyaluronidase

A. cold compress + dexrazoxane

41
New cards

Vinca alkaloids extravasation

A. cold compress + dexrazoxane

B. warm compress + hyaluronidase

B. warm compress + hyaluronidase

42
New cards

RITUXIMAB (target & safety)

• Target: CD20

• Safety: Hep B reactivation

43
New cards

CETUXIMAB (target & safety)

• Target: EGFR gene

• Safety: acneiform rash

44
New cards

TRASTUZUMAB (target & safety)

• Target: HER2 overexpression

• Safety: cardiotoxicity (monitor LVEF)

45
New cards

BEVACIZUMAB

• VEGF inhibitor

• Safety: impaired wound healing, thromboembolic events (HTN), bleeding, GI perforation

46
New cards

Bevacizumab should NOT be used for ____ days before or after surgery

28

47
New cards

PEMBROLIZUMAB

• PD-1 inhibitor

• Safety: immune mediated toxicities

48
New cards

IPILIUMUMAB

• CTLA-4 inhibitors

• Safety: immune mediated toxicities

49
New cards

IMATINIB (target & safety)

• Target: BCR-AL fusion gene

• Safety: fluid retention, QT prolongation

Tyrosine Kinase Inhibitor